Skip to main content
PMC home page
British Journal of Clinical Pharmacology logoLink to British Journal of Clinical Pharmacology
. 1984 Jul;18(1):57–63. doi: 10.1111/j.1365-2125.1984.tb05022.x

Antihypertensive and renal effects of nicardipine.

B A van Schaik, A E van Nistelrooy, G G Geyskes
PMCID: PMC1463589  PMID: 6743490

Abstract

Both the acute blood pressure lowering and renal effects of the calcium antagonist nicardipine and those after 1 week's treatment were investigated in 10 normotensive volunteers and in 10 patients with mild to moderate essential hypertension. After 1 week of placebo, nicardipine was administered orally for 1 week (20 mg three times daily), Investigations, done on the first and last day of nicardipine treatment were compared with those on the last day of placebo. During water loading, nicardipine increased urinary volume and urinary excretion of sodium significantly after 1 week nicardipine treatment. In the normotensive group the natriuretic effect was caused by a decrease of fractional proximal and distal reabsorption of sodium. In the hypertensive group the natriuresis was achieved mainly by an increase of the rate of glomerular filtration (GFR) and also by a slight distal effect. Our results show that nicardipine had natriuretic effects. There were trends suggesting that the renal effects may differ between patients with essential hypertension and normotensive volunteers, but the findings might also be related to differences in age between the groups.

Full text

PDF
57

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Abe Y., Komori T., Miura K., Takada T., Imanishi M., Okahara T., Yamamoto K. Effects of the calcium antagonist nicardipine on renal function and renin release in dogs. J Cardiovasc Pharmacol. 1983 Mar-Apr;5(2):254–259. doi: 10.1097/00005344-198303000-00015. [DOI] [PubMed] [Google Scholar]
  2. Aoki K., Kondo S., Mochizuki A., Yoshida T., Kato S., Kato K., Takikawa K. Antihypertensive effect of cardiovascular Ca2+-antagonist in hypertensive patients in the absence and presence of beta-adrenergic blockade. Am Heart J. 1978 Aug;96(2):218–226. doi: 10.1016/0002-8703(78)90089-3. [DOI] [PubMed] [Google Scholar]
  3. Fleckenstein A. Specific pharmacology of calcium in myocardium, cardiac pacemakers, and vascular smooth muscle. Annu Rev Pharmacol Toxicol. 1977;17:149–166. doi: 10.1146/annurev.pa.17.040177.001053. [DOI] [PubMed] [Google Scholar]
  4. Haber E., Koerner T., Page L. B., Kliman B., Purnode A. Application of a radioimmunoassay for angiotensin I to the physiologic measurements of plasma renin activity in normal human subjects. J Clin Endocrinol Metab. 1969 Oct;29(10):1349–1355. doi: 10.1210/jcem-29-10-1349. [DOI] [PubMed] [Google Scholar]
  5. Heidland A., Heidbreder E., Hörl W. H., Schäfer R. Calcium antagonists in the treatment of hypertension. Contrib Nephrol. 1982;33:254–269. doi: 10.1159/000407080. [DOI] [PubMed] [Google Scholar]
  6. Hiramatsu K., Yamagishi F., Kubota T., Yamada T. Acute effects of the calcium antagonist, nifedipine, on blood pressure, pulse rate, and the renin-angiotensin-aldosterone system in patients with essential hypertension. Am Heart J. 1982 Dec;104(6):1346–1350. doi: 10.1016/0002-8703(82)90166-1. [DOI] [PubMed] [Google Scholar]
  7. Klütsch K., Schmidt P., Grosswendt J. Der Einfluss von BAY a 1040 auf die Nierenfunktion des Hypertonikers. Arzneimittelforschung. 1972 Feb;22(2):377–380. [PubMed] [Google Scholar]
  8. Murakami M., Murakami E., Takekoshi N., Tsuchiya M., Kin T. Antihypertensive effect of (4-2'-nitrophenyl)-2,6-dimethyl-1,4-dihydropyridine-3,5-dicarbonic acid dimethylester (Nifedipine, Bay-a 1040), a new coronary dilator. Jpn Heart J. 1972 Mar;13(2):128–135. doi: 10.1536/ihj.13.128. [DOI] [PubMed] [Google Scholar]
  9. Ogihara T., Iinuma K., Nishi K., Arakawa Y., Takagi A. A non-chromatographic non-extraction radioimmunoassay for serum aldosterone. J Clin Endocrinol Metab. 1977 Oct;45(4):726–731. doi: 10.1210/jcem-45-4-726. [DOI] [PubMed] [Google Scholar]
  10. Olivari M. T., Bartorelli C., Polese A., Fiorentini C., Moruzzi P., Guazzi M. D. Treatment of hypertension with nifedipine, a calcium antagonistic agent. Circulation. 1979 May;59(5):1056–1062. doi: 10.1161/01.cir.59.5.1056. [DOI] [PubMed] [Google Scholar]
  11. Soto M. E., Thibonnier M., Sire O., Menard J., Corvol P., Milliez P. Antihypertensive and hormonal effects of single oral doses of captopril and nifedipine in essential hypertension. Eur J Clin Pharmacol. 1981;20(3):157–161. doi: 10.1007/BF00544592. [DOI] [PubMed] [Google Scholar]
  12. Takabatake T., Ohta H., Yamamoto Y., Maekawa M., Arai S., Hattori N., Nomura G. Antihypertensive effect of nicardipine hydrochloride in essential hypertension. Int J Clin Pharmacol Ther Toxicol. 1982 Aug;20(8):346–352. [PubMed] [Google Scholar]
  13. Taylor S. H., Silke B., Ahuja R. C., Okoli R. Influence of nicardipine on the blood pressure at rest and on the pressor responses to cold, isometric exertion, and dynamic exercise in hypertensive patients. J Cardiovasc Pharmacol. 1982 Sep-Oct;4(5):803–807. doi: 10.1097/00005344-198209000-00016. [DOI] [PubMed] [Google Scholar]
  14. Thibonnier M., Bonnet F., Corvol P. Antihypertensive effect of fractionated sublingual administration of nifedipine in moderate essential hypertension. Eur J Clin Pharmacol. 1980;17(3):161–164. doi: 10.1007/BF00561894. [DOI] [PubMed] [Google Scholar]
  15. Yokoyama S., Kaburagi T. Clinical effects of intravenous nifedipine on renal function. J Cardiovasc Pharmacol. 1983 Jan-Feb;5(1):67–71. doi: 10.1097/00005344-198301000-00010. [DOI] [PubMed] [Google Scholar]
  16. Yokoyama S., Kaburagi T. [Effects of intravenous nicardipine hydrochloride (YC 93), a calcium antagonist, on renal function (author's transl)]. Nihon Jinzo Gakkai Shi. 1981 Aug;23(8):1143–1151. [PubMed] [Google Scholar]

Articles from British Journal of Clinical Pharmacology are provided here courtesy of British Pharmacological Society

RESOURCES